Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-27 23:40 | 2025-03-25 | PRLD | Prelude Therapeutics Inc | Combs Andrew | Officer | BUY | $0.69 | 100,000 | $69,250 | 480,123 |
| 2025-03-27 23:37 | 2025-03-25 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | Director, Officer | BUY | $0.69 | 675,000 | $467,438 | 1,999,296 |
| 2025-03-27 16:56 | 2025-03-17 | ZOM | Zomedica Corp. | Rowe Jeffrey M | Director | BUY | $0.07 | 1,439,005 | $96,126 | 2,378,485 |
| 2025-03-28 01:53 | 2025-03-25 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $12.61 | 97,349 | $1,227,308 | 17,255,151 |
| 2025-03-27 14:30 | 2025-03-26 | ALZN | Alzamend Neuro Inc. | Horne William B. | Director | BUY | $0.99 | 3,334 | $3,285 | 30,000 |
| 2025-03-27 02:08 | 2025-03-24 | IRON | Disc Medicine, Inc. | Ashiya Mona | Director | SELL | $54.11 | 5,738 | $310,483 | 186,541 |
| 2025-03-26 23:41 | 2025-03-24 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer | SELL | $17.55 | 3,671 | $64,414 | 925,243 |
| 2025-03-27 00:41 | 2024-12-26 | XCUR | EXICURE, INC. | HiTron Systems Inc. | 10% owner | BUY | $3.00 | 2,900,000 | $8,700,000 | 3,333,333 |
| 2025-03-27 02:37 | 2025-03-24 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $22.50 | 1,000 | $22,505 | 23,000 |
| 2025-03-26 23:16 | 2025-03-25 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | OPT+S | $16.34 | 10,000 | $163,386 | 134,021 |
| 2025-03-26 23:05 | 2025-03-18 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $30.01 | 5,000 | $150,055 | 140,000 |
| 2025-03-26 23:30 | 2025-03-25 | TRVI | Trevi Therapeutics, Inc. | SCIASCIA THOMAS | Officer | OPT+S | $6.60 | 2,631 | $17,365 | 221,373 |
| 2025-03-26 23:05 | 2025-03-25 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $7.78 | 7,800 | $60,684 | 31,415 |
| 2025-03-26 23:03 | 2025-03-26 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $7.29 | 137,100 | $999,459 | 806,736 |
| 2025-03-27 02:01 | 2025-03-24 | CYRX | Cryoport, Inc. | Sawicki Mark W | Officer | SELL | $6.94 | 1,349 | $9,364 | 84,087 |
| 2025-03-27 02:00 | 2025-03-24 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | SELL | $6.94 | 1,070 | $7,428 | 190,349 |
| 2025-03-27 02:00 | 2025-03-24 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | SELL | $6.94 | 2,980 | $20,686 | 762,419 |
| 2025-03-27 01:55 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $60.58 | 421 | $25,504 | 9,009 |
| 2025-03-27 00:07 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $60.83 | 1,974 | $120,084 | 3,017,437 |
| 2025-03-27 00:07 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $60.58 | 1,697 | $102,804 | 85,622 |
| 2025-03-27 03:10 | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc. | Kihara James | Officer | OPT+S | $17.05 | 1,095 | $18,670 | 21,275 |
| 2025-03-27 03:06 | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | OPT+S | $17.05 | 3,171 | $54,066 | 56,889 |
| 2025-03-27 02:00 | 2025-03-24 | IRON | Disc Medicine, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $54.11 | 5,738 | $310,483 | 186,541 |
| 2025-03-27 00:04 | 2025-03-24 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | OPT+S | $14.00 | 10,000 | $140,000 | 8,078 |
| 2025-03-25 23:30 | 2025-03-21 | XOMA | XOMA Royalty Corp | Sitko Bradley | Officer | BUY | $23.89 | 4,134 | $98,751 | 2,800 |
| 2025-03-25 16:00 | 2025-03-24 | FGEN | KYNTRA BIO, INC. | Wettig Thane | Director, Officer | BUY | $0.35 | 145,000 | $50,663 | 543,329 |
| 2025-03-26 04:59 | 2025-03-21 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.43 | 25,750 | $11,132 | 384,272 |
| 2025-03-25 23:10 | 2025-03-21 | MRUS | Merus N.V. | Shuman Harry | Officer | OPT+S | $48.50 | 4,000 | $193,990 | 11,002 |
| 2025-03-26 00:15 | 2025-03-24 | IMNM | Immunome Inc. | Tsai Philip | Officer | BUY | $8.42 | 12,300 | $103,566 | 33,300 |
| 2025-03-26 01:46 | 2025-03-21 | LYEL | Lyell Immunopharma, Inc. | Ramachandra Sumant | Director | BUY | $0.58 | 200,000 | $115,220 | 200,000 |
| 2025-03-25 23:30 | 2025-03-21 | TRVI | Trevi Therapeutics, Inc. | GOOD JENNIFER L | Director, Officer | OPT+S | $6.58 | 5,263 | $34,625 | 213,313 |
| 2025-03-26 00:18 | 2025-03-24 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $8.21 | 7,000 | $57,470 | 23,615 |
| 2025-03-25 23:30 | 2025-03-21 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | BUY | $1.02 | 2,905 | $2,969 | 85,273 |
| 2025-03-25 23:10 | 2025-03-21 | ALNY | Alnylam Pharmaceuticals Inc. | Garg Pushkal | Officer | OPT+S | $293.36 | 9,766 | $2,864,985 | 20,221 |
| 2025-03-25 23:01 | 2025-03-21 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.00 | 174 | $1,740 | 2,824,844 |
| 2025-03-25 23:31 | 2025-03-24 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $318.80 | 2,500 | $796,991 | 8,480 |
| 2025-03-25 23:09 | 2025-03-24 | ALNY | Alnylam Pharmaceuticals Inc. | PYOTT DAVID E I | Director | OPT+S | $299.00 | 7,440 | $2,224,560 | 136 |
| 2025-03-25 04:00 | 2025-03-21 | ATAI | Atai Beckley N.V. | Kirpekar Sahil | Officer | SELL | $1.35 | 48,563 | $65,560 | 115,636 |
| 2025-03-25 04:00 | 2025-03-21 | ATAI | Atai Beckley N.V. | Craig Kevin James | Officer | SELL | $1.35 | 11,563 | $15,610 | 8,437 |
| 2025-03-25 04:00 | 2025-03-21 | ATAI | Atai Beckley N.V. | Rao Srinivas | Officer | SELL | $1.35 | 75,418 | $101,814 | 212,942 |
| 2025-03-25 04:00 | 2025-03-21 | ATAI | Atai Beckley N.V. | Johnson Anne Nagengast | Officer | SELL | $1.35 | 33,545 | $45,286 | 140,045 |
| 2025-03-25 04:00 | 2025-03-21 | ATAI | Atai Beckley N.V. | Short Glenn Frank | Officer | SELL | $1.35 | 13,161 | $17,767 | 42,333 |
| 2025-03-25 00:00 | 2025-03-24 | ATAI | Atai Beckley N.V. | Apeiron Investment Group Ltd. | 10% owner | BUY | $1.40 | 1,800,000 | $2,520,000 | 42,369,415 |
| 2025-03-25 03:00 | 2025-03-20 | IBO | IMPACT BIOMEDICAL INC. | DSS, INC. | 10% owner | BUY | $1.55 | 200 | $310 | 53,280 |
| 2025-03-25 03:00 | 2024-12-02 | IBO | IMPACT BIOMEDICAL INC. | DSS, INC. | 10% owner | SELL | $4.68 | 53,300 | $249,407 | 0 |
| 2025-03-24 23:35 | 2025-03-20 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $23.11 | 15,944 | $368,466 | 23,382 |
| 2025-03-25 00:03 | 2025-03-20 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | Director, Officer | BUY | $0.73 | 20,416 | $14,910 | 1,324,296 |
| 2025-03-24 14:30 | 2025-03-21 | ALZN | Alzamend Neuro Inc. | Katzoff David J | Officer | BUY | $1.01 | 5,000 | $5,048 | 5,540 |
| 2025-03-24 23:15 | 2025-03-20 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Zeiher Bernhardt G | Director | BUY | $3.70 | 10,000 | $37,005 | 10,000 |
| 2025-03-25 04:21 | 2025-03-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $10.92 | 750,000 | $8,190,750 | 1,127,290 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.